All In Biotech

Drug Trial Radar · NCT06907290

A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection

A Global, Randomized, Open-label, Multicenter, Phase 2b/3 Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-1)

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Mar 25, 2025

Primary completion

May 2029

Study completion Sep 2029

Sponsor

Lead sponsor
Mirum Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Apr 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2b/3 study designed to evaluate the safety and efficacy of chronic treatment with brelovitug (a.k.a BJT-778; BTG) for chronic hepatitis delta virus (HDV) infection. The comparator in this study will be 24-weeks of delayed treatment. During the 24-weeks of delayed treatment, participants will complete the same visits and assessments as those randomized to initiate brelovitug immediately. At the completion of 24-week delayed treatment period, all participants will start treatment with brelovitug.

Conditions

  • Chronic Hepatitis D Infection

Interventions

  • Brelovitug 300 mgDrug

    Route of administration- Subcutaneous Injection

  • Brelovitug 900 mgDrug

    Route of administration- Subcutaneous Injection

  • Delayed Treatment with Brelovitug 300mgDrug

    Route of administration- Subcutaneous Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with a composite endpointTime frame: Week 24

Locations

30 sites in 11 countries. Site status is shown where the registry gives one.

  • 252 Long Beach

    Long Beach, California

  • 244 Los Angeles

    Los Angeles, California

  • 251, Illinois

    Chicago, Illinois

  • 248 Lowa

    Cities in Iowa, Iowa

  • 254 Baltimore

    Baltimore, Maryland

  • 245 New York

    New York, New York

  • 256 New York

    New York, New York

  • 253 New York

    New York, New York

  • 255 New York

    New York, New York

  • 257 Philadelphia

    Philadelphia, Pennsylvania

  • 101 Camperdown

    Camperdown, Australia

  • 104 Liverpool

    Liverpool, Australia

  • 102 Melbourne

    Melbourne, Victoria, Australia

  • 705 Plovdiv

    Plovdiv, Bulgaria

  • 704 Stara Zagora

    Stara Zagora, Bulgaria

  • 703 Sliven

    Sliven, Silven, Bulgaria

  • 233 Calgary

    Calgary, Calgary, Canada

  • 234 Alberta

    Edmonton, Edmonton, Canada

  • 231 Toronto

    Toronto, Ontario, Canada

  • 235 Montreal

    Montreal, Quebec, Canada

  • 181 Tbilisi

    Tbilisi, Georgia

  • 183 Tbilisi

    Tbilisi, Georgia

  • 182 Tbilisi

    Tbilisi, Georgia

  • 211 Israel

    Beersheba, Israel

  • 212 Haifa

    Haifa, Haifa District, Israel

  • 901 Chisinau

    Chisinau, Moldova

  • 001 Auckland

    Auckland, New Zealand

  • 221 Karachi City

    Karachi, Karachi, Pakistan

  • 191 Istanbul

    Istanbul, Istanbul, Turkey (Türkiye)

  • 110 Kyiv

    Kyiv, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.